Henry Schein Inc (HSIC) Fair Value & Analysis
Healthcare · US · Market cap $10.0B · ISIN US8064071025
What is Henry Schein Inc really worth?
Henry Schein Inc
HSIC · US
A solid business, but trading 27% above our fair value of $71.70.
Strengths
Risks
Fair value as of: Aug 22, 2026
From 26 valuation models · updated 14 days ago
Share price +2.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($47.03 to $96.08) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range $61.89 – $91.96 · fair‑value band $47.03 – $96.08 · the $90.86 price screens above the $71.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Henry Schein Inc (HSIC) currently trades at $90.86, while our model-based Fair Value estimate is $71.70, implying the stock looks roughly 26.7% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the Dividend Discount group reads highest at a median of $276.77 per share, and 6 of the 26 models we run sit above the $90.86 price. Bear case: the Asset-Based group reads lowest at $19.09, and 20 of the 26 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Henry Schein Inc generated revenue of $13.4B at a net margin of 3.0%. Revenue grew 6.3% year over year. It earns a return on equity of 8.8%. Net debt stands at $3.5B. Fundamentals as of Aug 22, 2026
Our scenario range runs from $47.03 (bear case) to $96.08 (bull case); at $90.86, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades near its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 36% fair-value upside, at −21%, HSIC screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $2.25 per share, which is 3.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Dividend Discount ($276.77) versus Asset-Based ($19.09). Highest evidence: FCF DCF (78).
Notify me when HSIC reaches fair value
Put HSIC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.
Full company description
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Henry Schein Inc reported revenue of $13.2B in FY2025 versus $12.4B in FY2021, a compound +1.5%/yr. Reported net income was $398M in FY2025, compounding −10.6%/yr from FY2021.
of which total revenue +1.8 % · buybacks/dilution +3.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
HSIC screens 27% overvalued. Compare with McKesson Corporation →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis
- HSIC vs. SAUHY: Which Stock Is the Better Value Option?
- Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
- HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
Peer Group
Medical Distribution · 78 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $906.77 | $819.31 | −10% |
| Cencora, Inc COR | $330.97 | $211.07 | −36% |
| Cardinal Health, Inc CAH | $234.55 | $141.77 | −40% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.37 | ¥33.96 | +107% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | −24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.03 | ¥28.65 | +36% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 74.40 | kr 28.26 | −62% |
| China National Medicines Corporation 600511 | ¥26.84 | ¥58.22 | +117% |
Compare Henry Schein Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Henry Schein Inc (HSIC) overvalued or undervalued?
What is the fair value of HSIC?
What is the quality score of HSIC?
What is the revenue of Henry Schein Inc (HSIC)?
What is the net profit margin of HSIC?
Watch Henry Schein Inc in the live analysis
One click puts Henry Schein Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.